Saluda Medical Pty Ltd. news
Key data highlights with the Evoke® System to include holistic composite treatment outcomes for disrupting the chronic pain cycle; opioid-sparing effects of therapy; real-world results; and cost-effectiveness compared to open-loop stimulation.
Saluda Medical Pty Limited (“Saluda Medical”), a global medical device company revolutionizing the field of neuromodulation with
Transformative closed-loop technology senses the spinal cord’s response to stimulation and instantaneously adjusts therapy to sustain durable, optimized treatment
Long-term results published in two premier clinical journals show clinically meaningful improvements in pain relief, physical and emotional functioning, sleep quality, and health-related quality of life
Saluda Medical Pty Limited (“Saluda Medical”), a global medical device company
Saluda Medical Pty Limited (“Saluda Medical”), a global medical device company revolutionizing the field of neuromodulation with an emerging portfolio of therapies driven by advanced neural activation and sensing technologies designed to treat debilitating neurological disorders, today announced the appointment of Robert (Bob) Palmisano to its Board of Directors.
“Bob’s prolific experience as a public and private company CEO and extensive history in executive o
Saluda Medical Pty Limited (“Saluda Medical”), a global medical device company revolutionizing the field of neuromodulation with an emerging portfolio of therapies driven by advanced closed-loop technologies designed to treat debilitating neurological disorders, earlier this quarter finalized US $125 million in equity financing, led by existing investor Redmile Group LLC as well as new investors Fidelity Management & Research Company LLC, and funds and accounts advised by T. R
Saluda Medical Pty Limited (“Saluda Medical”), a global medical device company on a mission to revolutionize the field of neuromodulation with an emerging portfolio of therapies driven by advanced closed-loop technologies designed to treat debilitating neurological disorders, today announced the appointment of Doug Godshall as Chairman of its Board of Directors. Mr. Godshall succeeds Chris Beare, who has chaired the Saluda Board since 2011 and will remain a member of the Board.
Saluda Medical Pty Limited (“Saluda Medical”), a global company on a mission to revolutionize the field of neuromodulation with an emerging portfolio of therapies driven by advanced closed-loop technologies designed to treat debilitating neurological disorders, today announced long-term results of its double-blind Level 1 EVOKE randomized controlled trial (RCT) published online in JAMA Neurology. This follows the 12-month EVOKE Study res
Saluda Medical Pty Limited (“Saluda Medical”), the pioneer in neuromodulation platform of closed-loop technologies designed to achieve unparalleled outcomes for patients suffering from neurological conditions, today announced the expansion of the Company’s leadership team. Both executives bring years of professional accomplishments from the health technology industry and will play vital roles as the Company prepares for global commercialization.
Tim Benner will serve
Results show ~90% overall back and leg responder rate, ~68% high responder rate, and zero explants due to loss of efficacy
~83% of patients reduced or eliminated opioid use
Need for patient re-programming visits nearly eliminated after 12 months
Represents the first peer reviewed SCS study to show responder and high responder rate improvement over time
Saluda Medical
Saluda Medical Pty Limited (“Saluda Medical”), the market leader in the development of novel closed-loop spinal cord stimulation (SCS) for the treatment of chronic pain, today announced the appointment of Jim Schuermann as President & Chief Executive Officer. Mr. Schuermann joined Saluda Medical as President in June 2020. The company also announced that founder and CEO John Parker, PhD, will take on the new role of Chief Scientific Officer, while remaining on the company&rsquo
Saluda Medical Pty Limited (“Saluda Medical”), the market leader in the development of closed-loop spinal cord stimulation for the treatment of chronic pain, announced scientific highlights from the 2021 North American Neuromodulation Society (NANS 2021) Virtual Meeting, including real-world European commercial results and sub-analyses of 24-month and 12-month clinical data from the Avalon Australian Study and EVOKE investigational device exemption (IDE) Pivotal Study. Additionall